| Microorganism |
MIC50
(μg/ml) |
MIC90
(μg/ml) |
Range
(μg/ml) |
Antimicrobial |
Reference |
| Staphylococcus epidermidis (pansusceptible) |
0.015 |
0.015 |
0.008 － 0.5 |
API-1252  |
169 |
| Staphylococcus epidermidis (PAS9001) |
- |
- |
8 － ? |
Arylomycin |
783 |
| Staphylococcus epidermidis (penicillin-resistant) |
- |
1 |
? － ? |
Vancomycin (Vancocyn, Lyphocin) |
240 |
| Staphylococcus epidermidis (penicillin-resistant) |
- |
4 |
? － ? |
DuP-721 |
240 |
| Staphylococcus epidermidis (penicillin-susceptible clinical isolate) |
- |
- |
16 － ? |
Mefloquine |
276 |
| Staphylococcus epidermidis (preclinical isolate + methicillin-resistant) |
0.06 |
16 |
≤0.06 － 32 |
Rifampicin (Rifampin) |
477 |
| Staphylococcus epidermidis (preclinical isolate + methicillin-resistant) |
0.25 |
0.5 |
≤0.06 － 16 |
Quinupristin/Dalfopristin (Synercid) |
477 |
| Staphylococcus epidermidis (preclinical isolate + methicillin-resistant) |
0.25 |
16 |
≤0.06 － >=128 |
Ciprofloxacin (Cipro, Ciproxin, Ciprobay) |
477 |
| Staphylococcus epidermidis (preclinical isolate + methicillin-resistant) |
2 |
2 |
2 － 4 |
Vancomycin (Vancocyn, Lyphocin) |
477 |
| Staphylococcus epidermidis (preclinical isolate + methicillin-susceptible) |
≤0.06 |
≤0.06 |
≤0.06 － 16 |
Rifampicin (Rifampin) |
477 |
| Staphylococcus epidermidis (preclinical isolate + methicillin-susceptible) |
0.25 |
0.5 |
≤0.06 － 4 |
Quinupristin/Dalfopristin (Synercid) |
477 |
| Staphylococcus epidermidis (preclinical isolate + methicillin-susceptible) |
0.25 |
2 |
≤0.06 － >=128 |
Ciprofloxacin (Cipro, Ciproxin, Ciprobay) |
477 |
| Staphylococcus epidermidis (preclinical isolate + methicillin-susceptible) |
1 |
2 |
0.12 － 4 |
Vancomycin (Vancocyn, Lyphocin) |
477 |
| Staphylococcus epidermidis (preclinical isolate + methicillin-susceptible) |
2 |
8 |
≤0.06 － 32 |
Teicoplanin (Targocid) |
477 |
| Staphylococcus epidermidis (Q004) |
- |
- |
0.5 － ? |
Linezolid (PNU-100766, U-100766, Zyvox) |
224 |
| Staphylococcus epidermidis (Q004) |
- |
- |
1 － ? |
Vancomycin (Vancocyn, Lyphocin) |
224 |
| Staphylococcus epidermidis (quinolone-susceptible) |
0.12 |
0.25 |
0.12 － 0.25 |
Ciprofloxacin (Cipro, Ciproxin, Ciprobay) |
3 |
| Staphylococcus epidermidis (quinolone-susceptible) |
0.25 |
0.25 |
0.06 － 0.25 |
Levofloxacin (Levaquin, Quixin) |
3 |
| Staphylococcus epidermidis (RP62A) |
- |
- |
0.25 － ? |
Arylomycin |
783 |
| Staphylococcus epidermidis (SE1) |
- |
- |
0.12 － ? |
Retapamulin |
120 |
| Staphylococcus epidermidis (SE2) |
- |
- |
0.06 － ? |
Retapamulin |
120 |
| Staphylococcus epidermidis (SE3) |
- |
- |
0.06 － ? |
Retapamulin |
120 |
| Staphylococcus epidermidis (Sepi 1) |
- |
- |
0.12 － ? |
Mupirocin (Bactroban) |
120 |
| Staphylococcus epidermidis (Sepi 1) |
- |
- |
12 － ? |
Retapamulin |
120 |
| Staphylococcus epidermidis (Sepi 2) |
- |
- |
0.06 － ? |
Retapamulin |
120 |
| Staphylococcus epidermidis (Sepi 2) |
- |
- |
0.12 － ? |
Mupirocin (Bactroban) |
120 |
| Staphylococcus epidermidis (Sepi 3) |
- |
- |
0.06 － ? |
Mupirocin (Bactroban) |
120 |
| Staphylococcus epidermidis (Sepi 3) |
- |
- |
0.06 － ? |
Retapamulin |
120 |